<DOC>
	<DOC>NCT00946114</DOC>
	<brief_summary>The purpose of this study is to provide sildenafil therapy to eligible adult patients with pulmonary arterial hypertension (PAH) and to the patients who completed the A1481142 study for the treatment of PAH in Poland. Only safety and tolerability data will be collected in these patients.</brief_summary>
	<brief_title>To Provide Sildenafil Therapy To Eligible Adult Patients With Pulmonary Arterial Hypertension For 112 Weeks</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension, Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>1. Subjects aged 18 and over who have any of the following conditions: Idiopathic pulmonary arterial hypertension. PAH associated with connective tissue disease (CTD). PAH with surgical repair, at least 5yrs previously, of atrial septal defect (ASD), ventricular septal defect (VSD) patent ductus arteriosis (PDA) or aortapulmonary window. 2. Subjects with a mean pulmonary artery pressure (mPAP) &gt; 25mmHg and a pulmonary artery wedge pressure (PAWP) &lt; 15mmHg at rest, assessed via right heart catheterization. 3. Subjects whose baseline 6min walk test distance was &gt; 100m and &lt; 450m. 1. PAH secondary to any etiology other than those specified in the inclusion criteria. 2. Subjects with congenital heart disease (other than those specified in the inclusion criteria), PAH due to thromboembolism, HIV, chronic obstructive airways disease, congestive heart failure. 3. Subjects whose 6Minute Walk test might have been limited by conditions other than PAH, associated dyspnea or fatigue.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>